Skip to main content
Advertisement
  • Loading metrics

Coping with drug resistant tuberculosis alongside COVID-19 and other stressors in Zimbabwe: A qualitative study

  • Collins Timire ,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing

    Collins.Timire@lshtm.ac.uk

    Affiliations Faculty of Infectious & Tropical Diseases, Clinical Research Department, London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom, AIDS & TB Department, Ministry of Health and Child Care, Harare, Zimbabwe, Biomedical Research & Training Institute, The Health Research Unit, Harare, Zimbabwe

  • Katharina Kranzer,

    Roles Conceptualization, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliations Faculty of Infectious & Tropical Diseases, Clinical Research Department, London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom, Biomedical Research & Training Institute, The Health Research Unit, Harare, Zimbabwe, Division of Infectious Diseases & Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany

  • Debora Pedrazzoli,

    Roles Methodology, Supervision, Writing – review & editing

    Affiliation Faculty of Global and Public Health, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom

  • Fungai Kavenga,

    Roles Resources, Writing – review & editing

    Affiliation AIDS & TB Department, Ministry of Health and Child Care, Harare, Zimbabwe

  • Samuel Kasozi,

    Roles Resources, Writing – review & editing

    Affiliation AIDS & TB Department, Ministry of Health and Child Care, Harare, Zimbabwe

  • Fredrick Mbiba,

    Roles Data curation, Investigation, Validation, Writing – original draft, Writing – review & editing

    Affiliation Biomedical Research & Training Institute, The Health Research Unit, Harare, Zimbabwe

  • Virginia Bond

    Roles Conceptualization, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing

    Affiliations Faculty of Public Health and Policy, Department of Global Health and Development, LSHTM, London, United Kingdom, Zambart, Lusaka, Zambia

Abstract

Households in low-resource settings are more vulnerable to events which adversely affect their livelihoods, including shocks e.g. death of family members, droughts and more recently COVID-19. Drug Resistant Tuberculosis (DR-TB) is another shock that inflicts physical, psychological and socioeconomic burden on individuals and households. We describe experiences and coping strategies among people affected by DR-TB and their households in Zimbabwe during the COVID-19 pandemic, 2020–2021. We purposively selected 16 adults who had just completed or were completing treatment for DR-TB for in-depth interviews. We transcribed audio-recordings verbatim and translated the transcripts into English. Data were coded both manually and using NVivo 12 (QSR International), and were analysed thematically. Health seeking from providers outside the public sector, extra-pulmonary TB and health system factors resulted in delayed DR-TB diagnosis and treatment and increased financial drain on households. DR-TB reduced productive capacity and narrowed job opportunities leading to income loss that continued even after completion of treatment. Household livelihood was further adversely affected by lockdowns due to COVID-19, outbreaks of bird flu and cattle disease. Stockouts of DR-TB medicines, common during COVID-19, exacerbated loss of productive time and transport costs as medication had to be accessed from other clinics. Reversible coping strategies included: reducing number of meals; relocating in search of caregivers and/or family support; spending savings; negotiating with school authorities to keep children in school. Some households adopted irreversible coping strategies e.g. selling productive assets and withdrawing children from school. DR-TB combined with COVID-19 and other stressors and pushed households into deeper poverty and vulnerability. Multisectoral approaches that combine health systems and socioeconomic interventions are crucial to mitigate diagnostic delays and suffering, and meaningfully support people with DR-TB and their households to compensate the loss of livelihoods during and post DR-TB treatment.

Background

Tuberculosis (TB) is a global public health challenge, and until the COVID-19 pandemic, was the leading cause of death from a single infectious disease (ranking above HIV) [1]. An estimated 10.6 million people fell ill with TB in 2021 and 1.6 million (15%) of them died [1]. Treatment success (cure and treatment completion) for people with drug resistant TB (DR-TB) is worse, (averaging around 60% globally and around 54% in Zimbabwe) [24], compared to 86% for people with drug-susceptible TB (DS-TB) [5]. People with DR-TB have higher risk of loss to follow up, death and post-TB disabilities including poor lung function, auditory complications and, depending on site of infection, bone deformities [68].

Successful treatment outcomes among people with DR-TB depend on completing appropriate and efficacious course of medicines. Until very recently, treatment of DR-TB was much longer and more toxic than that of drug susceptible TB (DS-TB), lasting up to 18–24 months. As a result, people affected by DR-TB and their households often have to overcome even greater health system, psychosocial and socioeconomic barriers over an extended time before completing treatment [912]. Surveys of costs incurred by TB patients and their households have shown that a higher proportion of people affected by DR-TB incur catastrophic costs than those affected by DS-TB (82% vs 47%) [1315]. While the greater proportion of TB related costs are indirect costs such as income loss due to reduced productivity and time spent health seeking [16], people and their households also incur out-of-pocket costs which may be substantial to poor people who are less likely to have medical insurance, savings or stable earnings [17]. Health system approaches that have been implemented globally to reduce TB related costs include: i) early diagnosis of TB through systematic screening and universal access to drug susceptibility testing [18], ii) decentralisation of TB treatment to reduce transport costs, iii) provision of free TB medication and diagnostics and iv) provision of psycho-social and economic support. Notwithstanding these interventions, costs of hospitalisation, radiology services (chest X-rays), ancillary medicines, consultations and blood tests are often not considered [19], and individuals and their primary caregivers also incur substantial income loss (or indirect costs) related to taking time off work to seek and receive TB care [20,21]. Such indirect costs, together with costs related to food and transport to/from the health facility, constitute the major cost drivers [2022]. In addition to economic losses, households also experience worsening social relations and stigma [23]. Further shocks and stressors may affect households either concurrently or sequentially [24]. Such shocks may be spatial or covariate (e.g., COVID-19, drought, floods) when they affect communities, nations, regions or the whole world or may be temporal based on their occurrence (annual, seasonal) [25]. Often shocks have synergistic relationships that determine household coping strategies [24]. Poor and distressed households ― usually without medical insurance or savings ― may initially adopt reversible coping strategies such as delaying health seeking for chronic diseases, relocating in search of food or caregivers and spending savings. However, faced with acute infections or global shocks, they may be forced to mobilise and expend their resources rapidly [26]. Under such circumstances, they may adopt irreversible coping strategies such as taking loans at exorbitant interests, withdrawing children from school and selling productive assets, thereby deepening their vulnerability to current and future shocks [26,27]. COVID-19 is a global stressor and has been shown to be a stress multiplier [28]. Poor households that experience a convergence of DR-TB, COVID-19 and other stressors may have both a limited choice of coping strategies and limited coping capacity [29].

Zimbabwe, a resource limited country in sub Saharan Africa wracked with economic hardships and political instabilities since 2000, had an incidence of TB and DR-TB of 190 per 100,000 population and 4.9 per 100,000 population, respectively, in 2021, and TB/HIV co-infection was 50% [30,31]. Around 90% of the population is unemployed and earn a living through informal jobs (subsistence farming, informal businesses as vendors and cross border trading), and 72% live in poverty [32]. From March 2020-August 2020, the Zimbabwean government imposed a stringent lockdown with the aim to control the spread of COVID-19. During this time, businesses were shut and public transport almost completely ceased. Poor people, especially those in urban areas, faced an increased risk of contracting COVID-19 owing to overcrowded living conditions [33] and bore the brunt of lockdowns since they mostly live from daily earnings and are informally employed with no social security. In the absence of social support, COVID-19 thus negatively affected household income and food security. It is well established that poverty fuels both COVID-19 and TB and in turn, the two diseases deepen impoverishment and irreversible coping strategies [26,29]. Previous studies have looked at the impact of DR-TB, but not in the context of global shocks such as COVID-19 [9,34,35]. COVID-19 affected whole populations and impacted on health systems, livelihood and transportation. To study the joint impact of DR-TB, COVID-19 and other stressors, we conducted 16 in-depth interviews with people affected by DR-TB in Zimbabwe in 2020–2021 to trace their experiences and coping strategies during the pandemic and their period of treatment.

Methods

Management of DR-TB in Zimbabwe

In Zimbabwe, DR-TB care is provided at primary health care level. Prior to 2017, treatment duration was 18–24 months with daily injections for the first six months. From 2017, shorter (9–12 months) injection-based regimens were introduced followed by the introduction of a short all oral 9 months regimen in 2020 [36]. Xpert MTB/Rif (Cepheid, Sunnyvale, CA, USA) is the primary diagnostic test for people presenting with signs and symptoms of TB enabling not just diagnosis of TB, but also detection of rifampicin resistance [36]. People on DR-TB treatment are eligible for USD 25 conditional cash transfers and an additional USD 20 worth of grocery vouchers (from 2021 onwards) every month for the duration of treatment. However, delays and inconsistencies in cash disbursements and food hampers have been reported especially during the COVID-19 pandemic, with only two-thirds (64%) of those registered effectively receiving cash [37].

Study design, population and recruitment

This was a qualitative phenomenological study to gather lived experiences of people with DR-TB. Men and women aged ≥18 years who were within two months of completing DR-TB treatment or had completed treatment within two months were purposively sampled from TB registers within health facilities in Harare (urban) and Matebeleland South (rural) provinces in Zimbabwe. The study team met or called potential participants and appraised them about the study and how the study team obtained their names and contact details. Those who expressed willingness to participate in the study were asked to identify a convenient place and time so that the study team could obtain written informed consent and conduct in-depth interviews. Their sociodemographic details (age, sex, HIV status, history of TB and type of TB) were extracted from TB registers. Of the people whom the study team contacted, two could not attend the interviews because of family or work commitments. However, both had expressed willingness to participate in the study.

Data collection

In-depth interviews were conducted from October 2020 to March 2021 by CT (first author) and FM (social scientist), with CT conducting 12 interviews and FM four interviews. The themes in the interview guide, translated into two local languages (Shona and Ndebele), were developed based on published literature and by experiences of the research team in TB programming and treatment in Zimbabwe and Zambia. The interview guide was piloted with two people (male and female) with DR-TB. The results of the pilot interviews were not included in this study, but were used to finalize the interview guide. The interview guide explored health seeking patterns, experiences with DR-TB treatment and DR-TB disease and coping strategies adopted during treatment. Participants were asked to describe their experiences from the time they developed TB symptoms (including time it took them to seek healthcare once they started to feel sick, where they first sought care, delays they experienced when attending healthcare facilities and the money they spend throughout the diagnostic journey) until they were diagnosed with TB. They also described experiences from the time they started treatment to the day of the interview. Participants were also asked to detail the monetary and non-monetary losses they incurred as a result of TB and how they managed to cope with the socioeconomic impacts of TB. Experiences such as diagnostic delays and coping strategies were inferred from narrations. The interviews lasted 35–45 minutes and were conducted in Shona or Ndebele. All interviews were audio-recorded and were conducted in private locations suggested by participants. Participants received USD3 for refreshments and bus fares were reimbursed. After each interview, the two researchers (CT and FM) had debriefing meetings to discuss the findings and emerging themes to be explored further in subsequent interviews. This recurring process determined when data saturation was reached (where no more new information emerged) [38].

Ethical approval

Ethical approval was obtained from the London School of Hygiene and Tropical Medicine Research Ethics Committee (Ref 22579), the Biomedical Research and Training Institute Institutional Review Board (AP160/2020) and the Medical Research Council of Zimbabwe (MRCZ/A/2645). Permission to access DR-TB registers was obtained from the Permanent Secretary for Health, Zimbabwe. All participants gave written informed consent to take part in the study and for the use of an audio-recorder. Names used in quotes and tables in this paper are pseudonyms.

Data analysis

All audio-recordings were transcribed verbatim into MS Word in local languages by trained qualitative research assistants. In a second step, the Shona and Ndebele transcripts were translated verbatim into English and were typed in MS Word. CT who is fluent in Shona listened to the audios checking the accuracy of translations. Any translations that were inaccurate were discussed with FM to reach consensus. Ndebele transcripts and translations were checked by FM (fluent in Shona and Ndebele) and inaccurate translations were discussed with Ndebele speaking qualitative research assistants. Data were analyzed using thematic analysis. First, the transcripts were read several times aiming for familiarization with the data. Second, coding was done independently both manually on hard copies of transcripts and using NVivo version 12 software (QSR International) by CT and FM. The codes were both data driven and concept driven [39,40], and were grouped into themes to form thematic maps [41]. Both the codes and themes were shared with the study team to reduce subjectivity. Differences in coding and naming themes were resolved during discussion until consensus was reached. Divergent views were noted based on participant experiences at each stage and attempts were made to compare findings by gender, residency and whether one was previously treated of TB or not.

Results

Sixteen people (eight women) were enrolled. Twelve were co-infected with HIV. Their characteristics are summarized in Table 1. We first describe the experiences of people with DR-TB starting from delays in treatment initiation (due to underdiagnoses, misdiagnosis of TB or health seeking from alternative providers), physical impact of DR-TB disease and treatment itself, and changes in livelihoods as a result of DR-TB episodes. Next we explore the coping strategies adopted in response to DR-TB alongside other shocks, including COVID-19.

thumbnail
Table 1. Characteristics of DR-TB patients who were enrolled in the study, Zimbabwe, 2020–2021.

https://doi.org/10.1371/journal.pgph.0001706.t001

Delays in diagnosis and starting DR-TB treatment

Participants were asked to describe the journey they undertook from the time they developed TB symptoms to the time they received the DR-TB diagnosis. They described the places they visited, tests that were carried out and money they spent during the diagnostic phase. Ten of the 16 participants experienced delays of up to four months before they received a diagnosis and started DR-TB treatment. Reasons for delays included misdiagnosis, HIV co-infection and health seeking from alternative health providers such as traditional healers. Additional information is provided in Table 2.

Health system diagnostic delays

Reasons for delays in diagnosing DR-TB were multifactorial including the use of tests with low sensitivity (i.e., smear microscopy), lack of healthcare worker awareness and limited health system resources. The use of smear microscopy instead of Xpert MTB/Rif resulted in underdiagnosis of both TB and DR-TB. Smear microscopy has a lower sensitivity than Xpert MTB/Rif, especially in people living with HIV, and additionally cannot detect rifampicin resistance.

That’s when I went back to the same clinic and to the same nurses who had counselled me and I told them that I had not gained weight and they said, ‘Maybe you have TB. Let’s test you for TB’. When the results came out…they told me that I was TB negative. I was shocked to hear that I did not have TB. They asked me if I was taking my ARVs correctly. Ruth

Though Ruth was finally diagnosed with TB on the basis of smear microscopy, she was initially started on first line TB treatment. Similarly, Godfrey who had had TB in the past and according to the National TB Guidelines, should have been prioritised for Xpert MTB/Rif testing, was diagnosed using smear microscopy. Hence, he was started on first line treatment. While admitted in hospital, he benefitted from a doctor visiting the facility who requested an Xpert MTB/Rif test. Godfrey felt that he had wasted time on the wrong treatment.

He [the doctor] said, ‘I am not talking about the one [smear test] that is done at this hospital. You have to send a sputum sample to the reference laboratory’. They said they hadn’t. He then said, ‘This hospital does not have capacity to do some conclusive tests. What you are doing here are mere jokes’. Godfrey

…I had to forget about the previous two months of admission in hospital. It was a joke. [Laughs]. Godfrey

Diagnostic delays did not vary by participant gender. Even where Xpert MTB/Rif was available as a primary diagnostic test, Spiwe was wrongly started on first line TB treatment because healthcare workers misinterpreted the Xpert MTB/Rif result. As a result, Spiwe was on an ineffective TB treatment for at least three months.

I took it [first line TB treatment] from November, December to January. Then when I had gone to collect my re-supply in February they told me that I was taking a wrong treatment and was supposed to be on DR-TB treatment. Spiwe

Diagnosing DR-TB in people who have extrapulmonary TB requires invasive sampling. The equipment, consumables and expertise is not readily available in primary health care or district hospitals. Four participants with extra-pulmonary TB experienced delays in diagnosis and initiating appropriate treatment. All four were hospitalised before definite diagnoses were made and required costly laboratory tests and medical procedures that were outsourced to private facilities, as reflected in the experience of Talent.

… the injection [needle] they used was thick and long. They inserted it into my stomach and extracted some fluid from there. They took it to a private laboratory and that is how they discovered that I had TB in my stomach. Talent

Five participants experienced delays in turnaround time for follow-up laboratory results, especially during the COVID-19 pandemic. Changes from intensive to continuation phase regimens were only done once follow-up results were received. Longer intensive phase meant that participants were exposed to more drugs and side effects.

….so it [long processing times] delays you again from getting your results even though they always come late because of COVID. Felistus

Poor health seeking behaviour

Diagnosis of TB was also delayed among participants who first sought help from traditional healers or private clinics. Financial resources for such participants were depleted by the time they were referred to public health facilities. Caleb’s experience shows how some traditional healers would refer people to hospitals.

We were also advised by traditional healers to consult hospitals and other traditional healers. They mostly advised us to go to hospitals. That’s when we started going to X [a private clinic]. Caleb

We had spent all the money we had by the time I was referred to the doctors at X [TB referral centre] who confirmed that it was TB. Moses

By contrast, those who had had a previous TB episode accessed care earlier at public health facilities, since they were quick to recognise ‘possible TB’ symptoms. Such participants incurred little or no costs and were more likely to be physically fit when they started treatment.

I experienced chest pains and night sweats for less than a month. When I started having these symptoms, I said to myself, ‘Maybe the TB that previously infected me was not fully treated. Let me go to the clinic and get tested’. Then I went for testing and the results came out MDR-TB positive. Felistus

Health service factors undermining quality of TB care

In addition to the care seeking pre-diagnosis, participants described their experiences during treatment within health facilities. Once people were started on DR-TB treatment, they reflected on how they endured long waiting times at clinics and lack of privacy during administration of injections.

There is need for some form of privacy. I can’t pull down my trousers and get an injection while other nurses are watching from one of the rooms. Peter

Three participants were frustrated by lack of service continuity especially in urban clinics. Participants would meet new nurses at each clinic visit. These became more common during COVID-19 when some facilities were closed for fumigation and nurses redeployed to other facilities or services such as COVID-19 duties.

We knew each other very well with the nurse who was there and was supposed to administer my injections the week that followed. But that nurse did not come to work because she had been transferred and there was a new nurse. I had to start explaining to her all over again. Peter

Five participants reported that clinics experienced stock-outs of DR-TB drugs during the COVID-19 pandemic. They incurred additional costs because they were asked to travel to neighbouring clinics in search for medicines.

Sometimes I would board two commuter omnibuses to get to the clinic only to be told that the drugs were out of stock. They would then refer me to other clinics to check if the tablets were in stock. Moses

Participants living in urban settings were more likely to afford transportation costs compared to those in rural areas. A woman living in a rural village failed to access clofazimine, which meant that she had to go intermittently (during drug stockouts) without clofazimine. She was very frail although she was taking the medicines (except clofazimine) she managed to access religiously.

…I’m not getting all the drugs. There is one which was always in short supply; it is called clofazimine. So I wasn’t getting all the drugs for my treatment. I started getting them later. They gave me a full course last month. All along I was getting on an alternate basis. Spiwe

Talent who was on second-line antiretroviral therapy also experienced stock-outs of abacavir from public clinics resulting in a viral load rebound. She incurred substantial costs because she had to purchase abacavir from private pharmacies.

In the second line I had a challenge. I was taking Lopinavir and Abacavir. Abacavir is not available in all places. It’s hard to find. So I had a challenge in that abacavir was always out of stock. Being out of stock meant I had to buy it myself. So I would buy monthly supplies at USD7. So this caused my viral load to go down…to increase tremendously [correcting herself]. Talent

Physical and socioeconomic impact of DR-TB

We asked participants to detail both income and non-income losses they experienced as a result of TB. The impact of DR-TB on households was exacerbated by treatment delays, income instabilities and additional non-TB shocks. People who delayed DR-TB treatment were too frail to walk and work. They were often hospitalised and had to hire cars to visit health facilities because they could not walk from their house to bus stops and from bus stops to health facilities. Tecla incurred transportation costs which were in excess of USD375 due to car hire alone.

I wasn’t able to walk coz of weak joints and shortness of breath. So I had to hire a vehicle every day from July-December at R40 [USD2.50] per day. Tecla

Because of the side effects of DR-TB treatment, one man likened the medicines to ‘bulldozers’. Adherence to DR-TB medicines was difficult because of those side effects. The side effects also affected people’s productivity and ability to work. A participant explained that he had to make a tough choice between adhering to medicines and returning to work.

Those ones are like a bulldozer. They hit like a big hammer…[laughs]…That treatment hit me hard and made me very very weak and the injection caused me to sleep the whole day. Godfrey

Some of us we are in informal trades. Sometimes you would want to be consistent on [adhere to] your medication but it will force you to stop taking your medication and go for work because you can’t get on the street [informal job] when you have taken your medication. Peter

Households experienced huge losses of income during DR-TB treatment. Losses were related to reductions in productivity due to sickness and productive time lost while frequenting healthcare facilities and when household members could not attend to their work or daily chores because they were looking after a sick person. Loss of income was exacerbated by the informal nature of employment which does not reward and allow for absenteeism.

…my wife would support me to walk and would carry me on her back. So there was nothing else we could do for our living…My wife stopped doing piece [part-time] jobs because she was looking after me. Moses

…everything changed as soon as I was diagnosed with TB. You can’t get paid when you are not going to…to work. If you don’t go to work everything will also be on hold. Peter.

The physical, psychological and socioeconomic burden associated with DR-TB caused changes in traditional gender roles and strained marital relationships. This in turn led, in some cases, to abandonment by spouses and/or depression. Women were more likely to experience abandonment by spouses or family as compared to men. Felistus was abandoned by her aunt. Three women were abandoned by their husbands while men e.g. Moses and Caleb received support from their wives. Caleb was bedridden for a long time but his wife supported him throughout his disease. She even asked her family for financial support. Despite, the support from his wife, he contemplated suicide owing to the pain he went through.

…..after 8 months into my treatment that’s when my husband ran away from us and I was left alone. Life got tough for me and children. Up to now he hasn’t come back. I am still alone. Agnella

I said to my wife, ‘Umn, I have tried a lot to get healed.… I have cried a lot. It’s better for me that I go. May God give me rest; I am in pain!’ Caleb

Effect of shocks prevailing in environment in which people with TB live

In addition to the dire socioeconomic situation caused by DR-TB, COVID-19 lockdowns led to closure of businesses and forced households to spend their savings and to sell assets. Lockdowns closed a household business for Caleb and shattered job prospects for Godfrey who had recovered from DR-TB and was about to start a new job as a driver.

It took a long time before my wife re-opened her kitchen [canteen]. During lockdown, especially the first lockdown, people were not allowed to move… .that’s when our father sold his car. Life was tough. Caleb

Actually we depend on menial jobs. So as of now II was thinking ofwhat’s the name of those companies that are advertised in..? Those earth moving [machines]. So I was ready to go there unfortunately the COVID pandemic forced everything to a standstill. Godfrey.

Loss of income was aggravated when participants were abandoned by their breadwinner spouses. Even post DR-TB treatment, job opportunities were narrowed with limited prospects for people to recuperate and attain their pre-treatment income levels. Ruth who used to earn her livelihood as a hair stylist and was abandoned by her husband felt anxious to start working again.

It affected my marriage and my work. I was supposed to be busy plaiting hair right now. If I decide to plait hair, one of the clients may have dandruffs, and with this TB, I may get sick again. So it really affected me. Ruth

Rural households experienced additional shocks such as drought and pestilences. Pestilences, namely bird flu (Newcastle disease) and tickborne diseases (theileriosis), killed poultry and cattle respectively and amplified the negative effects of DR-TB on household livelihood.

That time our chickens got affected by bird flu. We used to rely on chickens for our relish…if you get sick you don’t want to eat substandard foods. Moses

Children were psychologically affected by seeing their parents suffer and in pain. Also they feared their parents might die. Talent explained that education of her child was affected in two ways: when the child refused to go to school and when the family could not afford school fees due to depleted financial resources.

‘What if I come back from school and find out that my mother is dead’ E-eh right now she was supposed to be in Form 2 but she is in Grade 7 because she refused to go to school. The other ones dropped out of school because as their mother I was not fit enough to run around looking for jobs and assistance. Talent

Coping strategies adopted by people and their households

We asked participants to explain how they managed to continue TB treatment despite the challenges they experienced. The coping strategies they adopted were categorised into either reversible or irreversible. All households adopted short term reversible coping strategies such as reducing number of meals and spending savings. Six people relocated to their families in search of support and/or caregivers.

It‘s like family support. Whenever I took my medication I’d get hungry and I was supposed to cook. I was supposed to…You know? I couldn’t do all of this. So I realized that it was better for me to go back home for maternal care and support. Peter

Support was often provided by immediate families.

…my father supported me a lot because that is when some of his pension came out. All of it was spent on my treatment. Loveness

Talent disclosed her DR-TB status to neighbours who assisted her with food and reminders to go to clinic to pick up her medications.

My neighbours would bring me food. In some cases, they would remind me that it was almost time to get to the clinic. I would thank them and tell them that I had fallen asleep. Then I would go [to the clinic].Talent

Households that either did not have savings or had spent their savings at the start of treatment initially sold non-productive and then productive assets to raise money for food and transport.

We sold chickens to get money to buy sugar, cooking oil or rice. That’s how we survived till we reached a point when she sold our spanners. She’d look around the house to find out if there was something else to sell so that we could get money for bus fare. Moses

Caleb’s livelihood as a private DJ was severely affected following the distress sale of his sound system. He deeply regretted the sale. He coped by making claims on family members to avert further sales of assets.

…I ended up selling assets that I wasn’t prepared to dispose. That PA (sound system) system! I am now thinking of replacing the speakers that I sold. Caleb

Uum. We realised that we had burdened people. So my wife ended up phoning my mother in-law. My mother-in-law would ask my father-in-law in Harare to send us some money for groceries. That helped us a lot. Caleb

Some households managed to register their children on a government educational social assistance programme. Those who failed to register their children tried to keep their children in school by negotiating with school authorities.

In terms of school fees BEAM [Basic Education Assistance Module] came to my rescue. I used to worry and to depend on my mother to pay school fees for my child…Tecla

We wanted to register them on BEAM but it seems one needs to have connections in order to get registered. Each time they were sent away from school for not paying fees, my wife would immediately go to the school to plead for their readmission. Moses

Discussion

Our study revealed huge socioeconomic, physical and psychological impacts of DR-TB among people and their household members, including children. DR-TB pushes households into a downward spiral of poverty and debt traps in a context such as Zimbabwe that has little safety nets and is wracked with economic challenges. Stock-outs of DR-TB drugs were frequently experienced during COVID-19. COVID-19 lockdowns affected people’s livelihoods as people depleted their savings. The convergence of COVID-19, economic challenges and other shocks such as pestilences amplified the impact of DR-TB on households, accelerating irreversible coping strategies such as selling productive assets and withdrawing children from school.

Diagnostic delays were a common theme in this study. Delays in starting TB treatment have been described in several settings [42,43]. Naidoo et al. observed that people delay care-seeking because they perceive the quality of services in public clinics as poor or believe that their symptoms are due to other causes [44]. In Zimbabwe, the time between onset of symptoms and start of DR-TB treatment was reported to be up to four months as people often sought care from private pharmacies and clinics first before they were diagnosed and referred to public clinics for treatment [42]. Our study shows that health system related factors contribute significantly to these delays [43]. Some of the participants of this study were initially started on first line TB treatment on the basis of smear microscopy results, due misinterpreting molecular results or because of difficulties in getting diagnostic specimens in the context of EPTB. Delayed diagnosis increases the likelihood of physical debility [45], community transmission of DR-TB, hospitalisation and income loss due to reduced productive capacity by sick people or when households members assume carer roles [46]. As expected, longer diagnostic journeys stretched household resources for a long time such that financial resources were depleted at commencement of DR-TB treatment [47]. DR-TB may break households resilience and may strain social relations with family, neighbours or spouses leading to abandonment, also documented in our study [45]. The End TB strategy aims to reduce TB morbidity and mortality by introducing WHO approved rapid diagnostics such as Gene Xpert to reduce the time to effective treatment [18]. The full benefits of such technology may not be realised unless delays and structural barriers within the health system are addressed [42,44]. By contrast, people who were diagnosed more rapidly (during either active TB case finding activities or sought healthcare early after recognising TB symptoms) had less severe disease at the time of treatment initiation and incurred less costs.

TB has long-term impacts on income and employment. DR-TB affected households are economically vulnerable even post TB treatment [6]. DR-TB narrows job opportunities and increases likelihood of post TB disabilities such as chronic lung disease. The disabilities result in households continuing to incur health care related costs [7,8,48,49]. In the same way, chronic disabilities as a result of TB or other diseases, recurring TB or additional shocks e.g. COVID-19 and pestilences may break household resilience to shocks faster, rendering households vulnerable to current and future TB [34].

The socioeconomic situation of DR-TB affected households, already strained due to their disease and related costs, was worsened by COVID-19. Studies have shown that households respond by utilising all resources available to them [26,27,50], and as observed in this study, may be forced to adopt irreversible coping strategies which had extensive impact on their livelihoods. As observed elsewhere, the impact of DR-TB, combined with COVID-19 was greatest on households without regular income and were food insecure, as they depleted their assets and exhausted short term coping strategies such as borrowing as they were no longer creditworthy [16,50,51]. In the context of distress sales, households may sell more assets to raise the amount of cash they need as assets are usually sold below their market values [34,50]. Though successful treatment outcomes were attained by all participants in this study, this was at the expense of their livelihoods.

Effective TB treatment requires uninterrupted supplies of medicines. Participants reported drug stock-outs during the first few months of the COVID-19 pandemic. This forced them to seek medicines in neighbouring clinics or go without certain medicines. Stockouts of drugs and diagnostics during COVID-19 occurred globally and were enhanced by transport and travel interruptions [52]. The National TB programme decided to dispense three-month supplies of medicines to reduce people’s contact with health facilities [53]. In the context of global supply chain disruptions and increased drug dispensing, stock-outs were therefore inevitable.

This study was conducted between the COVID-19 period (October 2020-February 2021), reducing the likelihood of recall bias. Most participants included in the study were initiated on DR-TB treatment during the first lockdown which allowed us to understand the challenges at the start of the pandemic. By including participants from rural and urban settings we were able to identify experiences and coping strategies which were setting specific. Participants who were interviewed were either at the end of treatment or had completed treatment providing insights into their diagnostic and treatment journeys. However, by interviewing participants at the end of successful treatment we introduced survival bias. Therefore, the challenges and coping strategies described here may not be representative of those doing less well on treatment. Studies have reported that DR-TB inflicts huge physical, socioeconomic and psychological impact on household members [12]. However, we only managed to infer the impact of DR-TB on household members based on what the participants affected by DR-TB reported since we did not interview any household members, spouses or children.

Our study has several implications for policy and practice. Firstly, since TB diagnosis is the entry point into treatment and care, delays in diagnosis should be addressed by fostering collaborations between private and public healthcare sectors and alternative health providers such as traditional healers [42,54], investing resources into earlier diagnosis using rapid diagnostic technology, communicating current TB guidelines to all healthcare workers, raising community awareness about signs and symptoms of TB and benefits of early health seeking from public facilities. Secondly, given the health seeking patterns observed in this study and other studies [42,44], public-private partnerships may enhance TB case finding in Zimbabwe as has been demonstrated in Vietnam [55,56]. Private pharmacies and clinics will have to be trained on screening for TB and referral systems for sputum specimens to public health laboratories for TB testing. They will also need TB guidelines, presumptive registers and registers to document all specimens they will refer for TB testing. Once TB is diagnosed, all treatment will be done in public facilities. Private facilities may be incentivised by cash per every case diagnosed with TB whom they would have referred. This will require effective monitoring to evaluate impact of private contribution to TB case notifications. Thirdly, the impact of DR-TB on physical, socioeconomic wellbeing of people and households calls for multidimensional measures that quantitatively measure both monetary and non-monetary impacts of TB on households [57]. If such measures are used, they may inform multisectoral approaches even beyond the treatment period, focusing on medical and social services for post TB care and measures to mitigate re-infection with DR-TB [35].

There are various social support systems provided by government agencies and non-governmental organisations in Zimbabwe including the USD25 cash disbursement every month for the duration of treatment for people on DR-TB treatment. However, evidence from this study and the patient cost survey conducted in Zimbabwe shows that this amount is unlikely to mitigate the costs and income loss experienced by DR-TB households [14]. Importantly, the coverage of the cash scheme is suboptimal and delays and inconsistencies in disbursements are frequent [37]. Additional safety nets in the form of educational assistance; payment of medical bills and extra food and money during and possibly post DR-TB treatment are therefore required. The Ministry of Public Service Labour and Social Welfare manages the Basic Education Assistance Module (for educational social assistance); the Harmonised Social Cash Transfers (for vulnerable households) and the Assisted Medical Treatment Order facility (for formal workers who experience work related disabilities). However, the Assisted Medical Treatment Order does not cover chronic conditions e.g. HIV and TB [58]. Several non-governmental organisations are providing various forms of assistance to vulnerable households within the communities in which we collected data, but their reach is chequered, and coordination between programs is limited and sometimes non-existent. Effective stakeholder mapping and inter-ministerial collaborations aimed at providing social protection to people and households with DR-TB should be included in the National Strategic Plan. People with DR-TB will need to be linked to available social protection. Given that many participants and households included in this study had experienced an episode of TB before and were vulnerable to future DR-TB, social protection should take a broader focus and should be availed before people and households are affected by DR-TB. Such TB sensitive approaches [59], that focus on food insecure or vulnerable households may have greater impact on TB epidemiology and control in Zimbabwe and will likely prevent future TB/DR-TB episodes.

Conclusion

DR-TB pushes households into poverty, and increases their vulnerability to shocks. Other stressors such as COVID-19 and pestilences enhanced their vulnerability resulting in irreversible coping strategies. The impact of DR-TB extends beyond the duration of DR-TB treatment. Multisectoral approaches combining health system, psychosocial and economic interventions are crucial to reduce diagnostic delays and mitigate physical and socioeconomic impacts of DR-TB and other shocks on households.

Supporting information

S1 Text. Transcripts: Coping with DR-TB and COVID-19.

https://doi.org/10.1371/journal.pgph.0001706.s001

(DOCX)

Acknowledgments

We would like to thank the participants who took part in this study.

References

  1. 1. World Health Organisation Global TB Report 2022; Geneva, Switzerland, 2022.
  2. 2. World Health Organisation Global Tuberculosis Report 2017; Geneva, Switzerland, 2017.
  3. 3. World Health Organisation Global Tuberculosis Report 2019; Geneva, Switzerland, 2019.
  4. 4. World Health Organization Global Tuberculosis Report 2016 –Tuberculosis Country Profiles; Geneva, Switzerland, 2016.
  5. 5. World Health Organisation Tuberculosis Profile: Global Available online: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&entity_type=%22group%22&group_code=%22global%22 (accessed on 10 May 2023).
  6. 6. Meghji J.; Gregorius S.; Madan J.; Chitimbe F.; Thomson R.; Rylance J.; et al. The Long Term Effect of Pulmonary Tuberculosis on Income and Employment in a Low Income, Urban Setting. Thorax 2021, 76, 387–395, pmid:33443228
  7. 7. Byrne A.L.; Marais B.J.; Mitnick C.D.; Garden F.L.; Lecca L.; Contreras C.; et al. Chronic Airflow Obstruction after Successful Treatment of Multidrug-Resistant Tuberculosis. ERJ Open Res 2017, 3, 1–11, pmid:28717643
  8. 8. Jabeen K. Pulmonary Infections after Tuberculosis. Int. J. Mycobacteriology 2016, Suppl 1, pmid:28043625
  9. 9. Isaakidis P.; Rangan S.; Pradhan A.; Ladomirska J.; Reid T.; Kielmann K. “I Cry Every Day”: Experiences of Patients Co-Infected with HIV and Multidrug-Resistant Tuberculosis. Trop. Med. Int. Heal. 2013, 18, 1128–1133, pmid:23837468
  10. 10. Chan E, D.; V, L.; Strand M, J.; Chan J, F.; Huynh M, N.; Goble M Treatment and Outcome Analysis of 205 Patients with Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med 2004, 169, 1103–1109. pmid:14742301
  11. 11. Ahuja S D.; Ashkin; Aventano; Benerjee; Bauer; Bayona Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-Analysis of 9,153 Patients. PLoS Med. 2012, 9, e1001300.
  12. 12. Yellappa V.; Lefèvre P.; Battaglioli T.; Narayanan D.; Van Der Stuyft P. Coping with Tuberculosis and Directly Observed Treatment: A Qualitative Study among Patients from South India. BMC Health Serv. Res. 2016, 16, 1–11, pmid:27430557
  13. 13. Fuady A.; Houweling T.A.J.; Mansyur M.; Richardus J.H. Catastrophic Total Costs in Tuberculosis- Affected Households and Their Determinants since Indonesia ‘ s Implementation of Universal Health Coverage. Infect. Dis. Poverty 2018, 7, 1–14, pmid:29325589
  14. 14. Timire C.; Ngwenya M.; Chirenda J.; Metcalfe J.Z.; Kranzer K.; Pedrazzoli D.; et al. Catastrophic Costs among Tuberculosis Affected Households in Zimbabwe: A National Health Facility-Based Survey. Trop. Med. Int. Heal. 2021, 26, 1248–1255. pmid:34192392
  15. 15. World Health Organisation National Surveys of Costs Faced by TB Patients and Their Households Available online: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/uhc-tb-determinants/6-2-national-surveys-of-costs-faced-by-tb-patients-and-their-households (accessed on 30 January 2023).
  16. 16. Ramma L.; Cox H.; Wilkinson L.; Foster N.; Cunnama L.; Vassall A.; et al. Patients’ Costs Associated with Seeking and Accessing Treatment for Drug-Resistant Tuberculosis in South Africa. Int. J. Tuberc. Lung Dis. 2015, 19, 1513–1519, pmid:26614194
  17. 17. University Research Co. LLC Providing Comprehensive Patient-Centred Care: A Conceptual Framework for Social Support for TB Patients; Bethesda, USA, 2014;
  18. 18. STOP TB Partnership The Paradigm Shift 2016–2020: Global Plan to End TB; Geneva, Switzerland, 2015.
  19. 19. Pedrazzoli D.; Lalli M.; Boccia D.; Houben R.; Kranzer K. Can Tuberculosis Patients in Resource-Constrained Settings Afford Chest Radiography? Eur. Respir. J. 2017, 49, 1601877, pmid:28182572
  20. 20. Ghazy R.M.; Saeh H.M. El; Abdulaziz S.; Hammouda E.A.; Elzorkany A.M.; Khidr H. OPEN A Systematic Review and Meta ‑ Analysis of the Catastrophic Costs Incurred by Tuberculosis Patients. Sci. Rep. 2022, 12, 1–16, pmid:35017604
  21. 21. World Health Organization Tuberculosis Patient Cost Surveys: A Handbook; Geneva, Switzerland, 2018;
  22. 22. Pedrazzoli D.; Siroka A.; Boccia D.; Bonsu F.; Nartey K.; Houben R.; Borghi J. How Affordable Is TB Care? Findings from a Nationwide TB Patient Cost Survey in Ghana. Trop. Med. Int. Heal. 2018, 23, 870–878, pmid:29851223
  23. 23. Hatherall B.; Newell J.N.; Emmel N.B.; Khan S.C.; Amir M. “Who Will Marry a Diseased Girl?” Marriage, Gender, and Tuberculosis Stigma in Asia. Qual. Health Res. 2019, 29, 1109–1119. pmid:30499375
  24. 24. Olsson L.; Maggie O.; Tschakert P.; Agrawal A.; Eriksen H, S.; Ma S.; et al. Livelihoods and Poverty. In Climate Change 2014: Impacts, Adaptation, and Vulnerability. Part A: Global and Sectoral Aspects. Contribution of Working Group II to the Fifth Assessment Report of the Intergovernmental Panel on Climate Change; Cambridge University Press: Cambridge, United Kingdom, 2014; pp. 798–799.
  25. 25. PEP-CBMS Network Coordinating Team. Definition and Types of Shocks and Coping Strategies to Be Monitored Available online: http://www.pep-net.org/sites/pep-net.org/files/typo3doc/pdf/CBMS_country_proj_profiles/Philippines/poverty_maps/Coping/Session2_Shocks_Coping_To_Monitor.pdf (accessed on 8 March 2020).
  26. 26. Diwakar, V. From Pandemics to Poverty: The Implications of Coronavirus for the Furthest Behind Available online: https://odi.org/en/insights/from-pandemics-to-poverty-the-implications-of-coronavirus-for-the-furthest-behind/ (accessed on 5 May 2022).
  27. 27. Russell S. Ability to Pay for Healthcare: Concepts and Evidence. Health Policy Plan. 2014, 11, 219–237, pmid:10160370
  28. 28. Shah S.M.A.; Mohammad D.; Qureshi M.F.H.; Abbas M.Z.; Aleem S. Prevalence, Psychological Responses and Associated Correlates of Depression, Anxiety and Stress in a Global Population, During the Coronavirus Disease (COVID-19) Pandemic. Community Ment. Health J. 2021, 57, 101–110, pmid:33108569
  29. 29. Diwakar V. From Pandemics to Poverty: Hotspots of Vulnerability in Times of Crisis; London, UK, 2020.
  30. 30. World Health Organisation Global TB Report 2020: Country Profiles; Geneva, Switzerland, 2020.
  31. 31. World Health Organisation Global Tuberculosis Report 2022; Geneva, Switzerland, 2022.
  32. 32. Ministry of Health and Child Care Zimbabwe National Health Financing Policy: Resourcing Pathway to Universal Health Coverage; Harare, Zimbabwe, 2015.
  33. 33. Chirisa I.; Mutambisi T.; Chivenge M.; Mabaso E.; Matamanda A.R.; Ncube R. The Urban Penalty of COVID-19 Lockdowns across the Globe: Manifestations and Lessons for Anglophone Sub-Saharan Africa. GeoJournal 2022, 87, 815–828, pmid:32868960
  34. 34. Vanleeuw L.; Zembe-Mkabile W.; Atkins S. “I’m Suffering for Food”: Food Insecurity and Access to Social Protection for TB Patients and Their Households in Cape Town, South Africa. PLoS ONEoS one 2022, 17, 1–16, pmid:35472210
  35. 35. Loveday M.; Hlangu S.; Larkan L.-M.; Cox H.; Daniels J.; Mohr-Holland E.; et al. “This Is Not My Body”: Therapeutic Experiences and Post-Treatment Health of People with Rifampicin-Resistant Tuberculosis. PLoS One 2021, 16, e0251482, pmid:34662887
  36. 36. Ministry of Health and Child Care Zimbabwe Tuberculosis Management Guidelines; Harare, Zimbabwe, 2016.
  37. 37. Timire C.; Sandy C.; Ferrand R.A.; Mubau R.; Shiri P.; Mbiriyawanda O.; et al. Coverage and Effectiveness of Conditional Cash Transfer for People with Drug Resistant Tuberculosis in Zimbabwe: A Mixed Methods Study. PLoS Glob. Public Heal. 2022, 2, e0001027, pmid:36962815
  38. 38. Saunders B.; Sim J.; Kingstone T.; Baker S.; Waterfield J.; Bartlam B.; et al. Saturation in Qualitative Research: Exploring Its Conceptualization and Operationalization. Qual. Quant. 2018, 52, 1893–1907, pmid:29937585
  39. 39. Bazeley P. Analysing Qualitative Data: More Than ‘ Identifying Themes.’ Malaysian J. Qual. Res. 2016, 2, 6–22.
  40. 40. Gibbs G.R. Analysing Qualitative Data; Sage Publications: London, UK, 2007;
  41. 41. Braun V.; Clarke V. Using Thematic Analysis in Psychology. Qual. Res. Psychol. 2006, 3, 77–101.
  42. 42. Tadokera R.; Huo S.; Theron G.; Timire C.; Manyau-Makumbirofa S.; Metcalfe J.Z. Health Care Seeking Patterns of Rifampicin-Resistant Tuberculosis Patients in Harare, Zimbabwe: A Prospective Cohort Study. PLoS One 2021, 16, e0254204, pmid:34270593
  43. 43. Shewade H.D.; Shringarpure K.S.; Parmar M.; Patel N.; Kuriya S.; Shihora S.; et al. Delay and Attrition before Treatment Initiation among MDR-TB Patients in Five Districts of Gujarat, India. Public Heal. Action 2018, 8, 59–65, pmid:29946521
  44. 44. Naidoo P.; van Niekerk M.; du Toit E.; Beyers N.; Leon N. Pathways to Multidrug-Resistant Tuberculosis Diagnosis and Treatment Initiation: A Qualitative Comparison of Patients’ Experiences in the Era of Rapid Molecular Diagnostic Tests. BMC Health Serv. Res. 2015, 15, 488, pmid:26511931
  45. 45. Bond V.; Chileshe M.; Sullivan C.; Magazi B. The Converging Impact of Tuberculosis, HIV/AIDS, and Food Insecurity in Zambia and South Africa. Renewal Working Paper; London, UK, 2009;
  46. 46. Department for International Development (DFID) Sustainable Livelihoods Guidance Sheets Available online: https://www.livelihoodscentre.org/documents/114097690/114438878/Sustainable+livelihoods+guidance+sheets.pdf/594e5ea6-99a9-2a4e-f288-cbb4ae4bea8b?t=1569512091877 (accessed on 12 May 2023).
  47. 47. Tanimura T.; Jaramillo E.; Weil D.; Raviglione M.; Lönnroth K. Financial Burden for Tuberculosis Patients in Low- and Middle-Income Countries: A Systematic Review. Eur. Respir. J. 2014, 43, 1763–1775, pmid:24525439
  48. 48. Chin A.T.; Rylance J.; Makumbirofa S.; Meffert S.; Vu T.; Clayton J.; et al. Chronic Lung Disease in Adult Recurrent Tuberculosis Survivors in Zimbabwe: A Cohort Study. Int J Tuberc Lung Dis 2019, 23, 203–211, pmid:30808453
  49. 49. Tadyanemhandu C.; Chirenda J.; Garvey C.; Metcalfe J. Treatment Success, but Living with the Consequences of Post-Tuberculosis Sequelae. Int. J. Tuberc. Lung Dis. 2020, 24, 657–658. pmid:32718395
  50. 50. Sweeney S.; Mukora R.; Candfield S.; Guinness L.; Grant D.A.; Vassall A. Measuring Income for Catastrophic Cost Estimates: Limitations and Policy Implications of Current Approaches. Soc. Sci. Med. 2018, 215, 7–15. pmid:30196149
  51. 51. Foster N.; Vassall A.; Cleary S.; Cunnama L.; Churchyard G.; Sinanovic E. The Economic Burden of TB Diagnosis and Treatment in South Africa. Soc. Sci. Med. 2015, 130, 42–50, pmid:25681713
  52. 52. European Medicines Agency Availability of Medicines during COVID-19 Pandemic Available online: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/availability-medicines-during-covid-19-pandemic (accessed on 8 January 2023).
  53. 53. Sandy C.; Takarinda K.C.; Timire C.; Mutunzi H.; Dube M.; Dlodlo R.A.; et al. Preparing National Tuberculosis Control Programmes for COVID-19. Int. J. Tuberc. Lung Dis. 2020, 24, 634–636, pmid:32553013
  54. 54. Shringarpure K.S.; Isaakidis P.; Sagili K.D.; Baxi R.K.; Das M.; Daftary A. “When Treatment Is More Challenging than the Disease”: A Qualitative Study of MDR-TB Patient Retention. PLoS One 2016, 11, e0150849, pmid:26959366
  55. 55. Quy H.T.; Lan N.T.N.; Lönnroth K.; Buu T.N.; Dieu T.T.N.; Hai L.T. Public-Private Mix for Improved TB Control in Ho Chi Minh City, Vietnam: An Assessment of Its Impact on Case Detection. Int. J. Tuberc. Lung Dis. 2003, 7, 464–471. pmid:12757048
  56. 56. Thu T. Do; Kumar A.M. V; Ramaswamy G.; Htun T.; Van H. Le; Quang L.V.N.; et al. An Innovative Public-Private Mix Model for Improving Tuberculosis Care in Vietnam: How Well Are We Doing? Trop. Med. Infect. Dis. 2020, 5, 26, pmid:32075073
  57. 57. Timire C.; Pedrazzoli D.; Boccia D.; MGJ R.; Houben ; Ferrand R.A.; et al. Use of a Sustainable Livelihood Framework-Based Measure to Estimate Socioeconomic Impact of Tuberculosis on Households. Clin. Infect. Dis. 2023, ciad273, pmid:37132328
  58. 58. Ministry of Health and Child Care Contact Investigation Guidelines; Harare, Zimbabwe, 2019;
  59. 59. Boccia D.; Pedrazzoli D.; Wingfield T.; Jaramillo E.; Lönnroth K.; Lewis J.; et al. Towards Cash Transfer Interventions for Tuberculosis Prevention, Care and Control: Key Operational Challenges and Research Priorities. BMC Infect. Dis. 2016, 16, 1–12, pmid:27329161